0001650664 2026-08-28 2026-08-28 0001650664 1 2026-08-28 2026-08-28 0001650664 2 2026-08-28 2026-08-28 0001650664 3 2026-08-28 2026-08-28 0001650664 4 2026-08-28 2026-08-28 0001650664 5 2026-08-28 2026-08-28 0001650664 6 2026-08-28 2026-08-28 0001650664 7 2026-08-28 2026-08-28 0001650664 8 2026-08-28 2026-08-28 0001650664 9 2026-08-28 2026-08-28 iso4217:USD pure S-3 S-3 EX-FILING FEES 0001650664 Editas Medicine, Inc. N/A N/A 0.0001381 0.0001381 0.0001381 0.0001381 0.0001381 0.0001381 0.0001381 0.0001381 S-3 Editas Medicine, Inc. Debt Debt Securities true Equity Common Stock, par value $0.0001 per share true Equity Preferred Stock, par value $0.0001 per share true Other Depositary Shares true Other Subscription Rights true Other Purchase Contracts true Other Warrants true Other Units true false Unallocated (Universal) Shelf true 400000000.00 0.0001381 55240.00 400000000.00 55240.00 0.00 0.00 55240.00 Pursuant to Instruction 2.A(iii)(b) of Item 16(b) of Form S-3, this information is not required to be included. An indeterminate amount of the securities of each identified class is being registered as may from time to time be offered under this registration statement at indeterminate prices, along with an indeterminate number of securities that may be issued upon exercise, settlement, exchange or conversion of securities offered or sold under this registration statement, as shall have an aggregate initial offering price of up to $400,000,000. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities. Separate consideration may or may not be received for securities that are issuable upon conversion, exercise or exchange of other securities. In addition, the total amount to be registered and the proposed maximum offering price are estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act. Each depositary share will be issued under a deposit agreement, will represent an interest in a fractional share or multiple shares of preferred stock and will be evidenced by a depositary receipt. The subscription rights to purchase shares of common stock or preferred stock or other securities will be offered without additional consideration. Each purchase contract will be issued under a purchase agreement and will obligate holders to purchase from or sell to Editas Medicine, Inc. and obligate Editas Medicine, Inc. to sell to or purchase from the holders, a specified number of shares of common stock, preferred stock or depositary shares. The warrants covered by this registration statement may be warrants for common stock, preferred stock, depositary shares or debt securities. The purchase contracts will be issued separately or as a part of units consisting of a purchase contract and either shares of common stock, shares of preferred stock, debt securities, debt obligations of third parties securing the holder's obligations to purchase the securities under the share purchase contracts or the rights to purchase any securities under this registration statement. Units may be issued under a unit agreement and will represent an interest in one or more securities registered under this registration statement including shares of common stock or preferred stock, debt securities, depositary shares, subscription rights, warrants or purchase contracts, in any combination, which may or may not be separable from one another.